Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2021

View Archived Issues

Ascentage Pharma polycomb protein EED inhibitor displays potency, tumor regression potential

FPR2 agonist NAP-1051 shows promise in preclinical SLE model

SCO-spondin-derived peptide shows neuroprotection and increased synaptic transmission in the CNS

Calreticulin as promising new therapeutic target in breast cancer

PharmaMar describes HER2-targeting antibody-drug conjugates

New MAP4K1 inhibitors discovered at Wigen Biomedicine Technology

Roche patents potassium voltage-gated channel subfamily C member 1 activators

New compounds inhibiting respiratory syncytial virus identified at Janssen

Boehringer Ingelheim presents new HER2 inhibitors

COVA1-18 demonstrates strong antiviral activity against SARS-CoV-2 in vivo

DDR1 promotes immune exclusion in tumors and it is a therapeutic target

Cannabigerol derivatives have anti-inflammatory, analgesic and antiobesity potential

Circulating levels of galectin-1 associated with lower kidney function

Rakovina presents data on in vitro activity of novel dual PARP-HDAC inhibitors

Study shows gut microbiome changes may be effect, not cause, of autism spectrum disorders

Opus Genetics licenses new preclinical program for inherited retinal disease

ITIH4 is a marker for early diagnosis of gastric cancer

Fitness cost of antibiotic-resistant mutants can be used to identify new combination therapies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...